公开(公告)号：WO2008106115A3

公开(公告)日：2008-11-27

申请号：PCT/US2008002497

申请日：2008-02-26

Applicant: MONOGRAM BIOSCIENCES INC ,  HUANG WEI ,  FRANSON SIGNE ,  PETROPOULOS CHRISTOS J ,  TOMA JONATHAN ,  WHITCOMB JEANNETTE

Inventor： HUANG WEI ,  FRANSON SIGNE ,  PETROPOULOS CHRISTOS J ,  TOMA JONATHAN ,  WHITCOMB JEANNETTE

IPC: C12Q1/70 ,  A61K39/395 ,  G01N33/566

CPC classification number: C12Q1/703 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/56988 ,  G01N2333/16 ,  G01N2333/162 ,  G01N2800/52

Abstract: The present invention provides methods and compositions for determining whether a subject would benefit from co-receptor inhibitor therapy. In certain aspects, the methods can be used to determine whether a subject infected with a dual -mixed tropic population of HIV would benefit from CCCR5 -inhibitor therapy or CXCR4-inhibitor therapy, the methods comprising determining whether the HIV population is a homogeneous or heterogeneous population of HIV, wherein the nature of the homogenous or heterogenous population of HIV indicates whether the patient would benefit from co-receptor inhibitor therapy.

Abstract translation: 本发明提供了用于确定受试者是否将受益于共受体抑制剂治疗的方法和组合物。 在某些方面，所述方法可用于确定感染HIV的双重混合热带人群的受试者是否将受益于CCCR5抑制剂治疗或CXCR4抑制剂治疗，所述方法包括确定HIV群体是否是均质的或异质性的 艾滋病毒的人群，其中艾滋病的同源或异质群体的性质表明患者是否可以从共同受体抑制剂治疗中受益。

公开(公告)号：WO2008106115A2

公开(公告)日：2008-09-04

申请号：PCT/US2008/002497

申请日：2008-02-26

Applicant: MONOGRAM BIOSCIENCES, INC. ,  HUANG, Wei ,  FRANSON, Signe ,  PETROPOULOS, Christos, J. ,  TOMA, Jonathan ,  WHITCOMB, Jeannette

Inventor： HUANG, Wei ,  FRANSON, Signe ,  PETROPOULOS, Christos, J. ,  TOMA, Jonathan ,  WHITCOMB, Jeannette

IPC: C12Q1/70

CPC classification number: C12Q1/703 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/56988 ,  G01N2333/16 ,  G01N2333/162 ,  G01N2800/52

Abstract: The present invention provides methods and compositions for determining whether a subject would benefit from co-receptor inhibitor therapy. In certain aspects, the methods can be used to determine whether a subject infected with a dual -mixed tropic population of HIV would benefit from CCCR5 -inhibitor therapy or CXCR4-inhibitor therapy, the methods comprising determining whether the HIV population is a homogeneous or heterogeneous population of HIV, wherein the nature of the homogenous or heterogenous population of HIV indicates whether the patient would benefit from co-receptor inhibitor therapy.

Abstract translation: 本发明提供了用于确定受试者是否将受益于共受体抑制剂疗法的方法和组合物。 在某些方面，所述方法可用于确定感染HIV双重混合热带人群的受试者是否将受益于CCCR5抑制剂治疗或CXCR4抑制剂疗法，所述方法包括确定HIV群体是同质的还是异质的 其中HIV的同质或异质群体的性质表明患者是否将受益于共受体抑制剂治疗。